AllergyTalk: The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries - Episode 1: The Limitations of Bronchodilator Only Rescue Therapy (Non-CME)
The discussion explores the limitations of bronchodilator-only rescue therapy and explains the rationale for changing the recommended asthma rescue therapy to improve asthma exacerbations and align with patient preferences.
Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: pathophysiology, exacerbations, anti-inflammatory reliever (AIR), SMART therapy.
Host: Gerald B. Lee, MD, FACAAI
Experts: William C. Anderson III, MD, FACAAI; Alan P. Baptist, MD, MPH, FACAAI
CME is not offered for this podcast.
Reference:
Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252.
This podcast miniseries is supported by a grant from AstraZeneca.
Target Audience
Primary Care Providers
Fellows-in-Training
Learning Objectives
After listening to this podcast miniseries, participants should be better able to:
- Expose the prevalence of asthma and exacerbations in the US
- Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic
- Realize both the genomic and nongenomic mechanisms of action of inhaled asthma therapies
- Analyze the latest expert opinion on treatment of asthma to mitigate morbidity
Gerald B. Lee, MD, FACAAI
No relevant financial relationships with ineligible companies to disclose
William C. Anderson III, MD, FACAAI
Advisor: Genentech, Regeneron, Sanofi
Alan P. Baptist, MD, MPH, FACAAI
Advisor: AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi
Researcher: AstraZeneca, Novartis, Regeneron